AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28574378 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching from atorvastatin to rosuvastatin after 6 months
Number of subjects: 0
Study 28574378 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin and rosuvastatin (without switching)
Number of subjects: 0
Study 26571012 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (30 g/day for 2 weeks)
Number of subjects: 40
Study 26571012 — intervention group
Group type: COMPARATOR
Intervention: Cellulose (control)
Number of subjects: 40
Study 24710248 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIPA
Number of subjects: 124
Study 24710248 — intervention group
Group type: COMPARATOR
Intervention: LMA ProSeal
Number of subjects: 124
Study 22781876 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 998
Study 19165412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral prophylactic ureteral catheterization
Number of subjects: 1583
Study 19165412 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic ureteral catheterization
Number of subjects: 1583
Study 17578359 — intervention group
Group type: EXPERIMENTAL
Intervention: Monsel's solution
Number of subjects: 285
Study 17578359 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 285
Study 15368689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure device for radical prostatectomy
Number of subjects: 58
Study 15368689 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure device for radical cystectomy
Number of subjects: 58
Study 15368689 — intervention group
Group type: COMPARATOR
Intervention: Conventional ligation for radical prostatectomy
Number of subjects: 58
Study 15368689 — intervention group
Group type: COMPARATOR
Intervention: Conventional ligation for radical cystectomy
Number of subjects: 58
Study 11108415 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing 20 g of protein and 800 mg of calcium for 60 days
Number of subjects: 171
Study 11108415 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 60 days
Number of subjects: 171
Study 9092165 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoprosthesis of biocompatible polymers
Number of subjects: 15
Study 9092165 — intervention group
Group type: COMPARATOR
Intervention: Endoprosthesis of silicon rubber
Number of subjects: 15
Study 8382934 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of OPC‐17116 (400 mg)
Number of subjects: 15
Study 8382934 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of OPC‐17116 (400 mg day‐1, twice daily, for 6.5 days)
Number of subjects: 15
Study 8382934 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC‐17116 (300 mg day‐1, three times daily, for 2 days)
Number of subjects: 15
Study 3455717 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 77
Study 3455717 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus ACNU
Number of subjects: 77
Study 31915883 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761®
Number of subjects: 202
Study 29506685 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Monitoring (RM)
Number of subjects: 339
Study 29506685 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 339
Study 27929530 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (⩾5 min)
Number of subjects: 73
Study 27929530 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC) (<20 s)
Number of subjects: 73
Study 26209097 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor guided multi-component intervention including medication adjustment, stepped care for anxiety/depression, and exercise therapy.
Number of subjects: 0
Study 26209097 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factor guided multi-component intervention
Number of subjects: 0
Study 24257456 — intervention group
Group type: EXPERIMENTAL
Intervention: Orsiro Hybrid sirolimus‐eluting stent
Number of subjects: 375
Study 24257456 — intervention group
Group type: COMPARATOR
Intervention: Resolute Integrity zotarolimus‐eluting stent
Number of subjects: 375
Study 20367790 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-rhIFN-α(2b) 160 μg every 2 weeks for 12 weeks with ribavirin
Number of subjects: 32
Study 20367790 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-rhIFN-α(2b) 320 μg every 2 weeks for 12 weeks with ribavirin
Number of subjects: 32
Study 20367790 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-rhIFN-α(2b) 480 μg every 2 weeks for 12 weeks with ribavirin
Number of subjects: 32
Study 20367790 — intervention group
Group type: EXPERIMENTAL
Intervention: CR-rhIFN-α(2b) 640 μg every 2 weeks for 12 weeks with ribavirin
Number of subjects: 32
Study 18719760 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdisciplinary care
Number of subjects: 153
Study 18719760 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 153
Study 17166806 — intervention group
Group type: COMPARATOR
Intervention: Bimanual tasks
Number of subjects: 26
Study 17166806 — intervention group
Group type: COMPARATOR
Intervention: Unimanual tasks
Number of subjects: 26
Study 17166806 — intervention group
Group type: COMPARATOR
Intervention: Optimal trajectories
Number of subjects: 26
Study 12877758 — intervention group
Group type: EXPERIMENTAL
Intervention: β1-selective β-blockers (nebivolol)
Number of subjects: 171
Study 12877758 — intervention group
Group type: EXPERIMENTAL
Intervention: DHPCCB (amlodipine, felodipine, isradipine, nifedipine)
Number of subjects: 171
Study 10741935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 20 mg
Number of subjects: 201
Study 10741935 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 201
Study 8941053 — intervention group
Group type: EXPERIMENTAL
Intervention: Seprafilm (HAL-F)
Number of subjects: 127
Study 8941053 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 127
Study 1313078 — intervention group
Group type: EXPERIMENTAL
Intervention: L-threonine (2 g daily)
Number of subjects: 15
Study 1313078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31500139 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training with carbohydrate administration before each session
Number of subjects: 23
Study 31500139 — intervention group
Group type: COMPARATOR
Intervention: Endurance training without carbohydrate administration
Number of subjects: 23
Study 31500139 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training with carbohydrate administration
Number of subjects: 23
Study 31500139 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 23
Study 28294318 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of Killing (IOK) treatment (N = 17)
Number of subjects: 33
Study 28294318 — intervention group
Group type: COMPARATOR
Intervention: 6-week waitlist condition (Control, N = 16)
Number of subjects: 33
Study 25728731 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineralocorticoid receptor antagonists (MRAs) therapy
Number of subjects: 151
Study 25728731 — intervention group
Group type: COMPARATOR
Intervention: No MRA therapy
Number of subjects: 151
Study 24026142 — intervention group
Group type: EXPERIMENTAL
Intervention: ramipril (ACE‐I)
Number of subjects: 439
Study 24026142 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan (ARB)
Number of subjects: 439
Study 24026142 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (diuretic)
Number of subjects: 439
Study 24026142 — intervention group
Group type: COMPARATOR
Intervention: amlodipine (CCB)
Number of subjects: 439
Study 22174074 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical administration of standardized extract from Ageratina pichinchensis
Number of subjects: 34
Study 22174074 — intervention group
Group type: COMPARATOR
Intervention: 7% propylene glycol alginate (control)
Number of subjects: 34
Study 19356392 — intervention group
Group type: EXPERIMENTAL
Intervention: TDS-testosterone
Number of subjects: 12
Study 19356392 — intervention group
Group type: COMPARATOR
Intervention: Androgel
Number of subjects: 12
Study 18025807 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% glycerol-based emollient
Number of subjects: 24
Study 18025807 — intervention group
Group type: COMPARATOR
Intervention: Glycerol-free placebo
Number of subjects: 24
Study 16159535 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month tapering of antiepileptic drug
Number of subjects: 57
Study 16159535 — intervention group
Group type: COMPARATOR
Intervention: 6-month tapering of antiepileptic drug
Number of subjects: 57
Study 12447120 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby walkers
Number of subjects: 0
Study 12447120 — intervention group
Group type: COMPARATOR
Intervention: No baby walkers (control group)
Number of subjects: 0
Study 9894689 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfortable position during object manipulation
Number of subjects: 0
Study 9894689 — intervention group
Group type: EXPERIMENTAL
Intervention: Small target condition
Number of subjects: 0
Study 9894689 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinpoint target condition
Number of subjects: 0
Study 7573271 — intervention group
Group type: COMPARATOR
Intervention: Management without seizure prophylaxis
Number of subjects: 467
Study 7573271 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 467
Study 7573271 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic hypertension with superimposed preeclampsia
Number of subjects: 467
Study 1963701 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP 200 mg/m2 administered in arm A (100 mg/m2 on Day 1 and Day 8)
Number of subjects: 57
Study 1963701 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP 200 mg/m2 administered in arm B (40 mg/m2 per day during 5 consecutive days)
Number of subjects: 57
Study 6992711 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 80
Study 6992711 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 80
Study 30417710 — intervention group
Group type: COMPARATOR
Intervention: ART-Def
Number of subjects: 0
Study 30417710 — intervention group
Group type: EXPERIMENTAL
Intervention: ART-Immed
Number of subjects: 0
Study 30417710 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-exposed-uninfected
Number of subjects: 0
Study 28162873 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop drainage
Number of subjects: 46
Study 28162873 — intervention group
Group type: COMPARATOR
Intervention: Standard incision & drainage (I&D)
Number of subjects: 46
Study 25690082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP)
Number of subjects: 0
Study 25690082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24330656 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified visual probe task with attentional retraining
Number of subjects: 0
Study 24330656 — intervention group
Group type: COMPARATOR
Intervention: Placebo training
Number of subjects: 0
Study 24330656 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 21 mg transdermal nicotine patches for 8-12 weeks and withdrawal-oriented behavioural support for 7 sessions
Number of subjects: 0
Study 20562711 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic plus strength training
Number of subjects: 20
Study 20562711 — intervention group
Group type: COMPARATOR
Intervention: Aerobic interval training
Number of subjects: 20
Study 20562711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 19302015 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LEDT cluster-probe (660/850 nm, 10/30 mW)
Number of subjects: 8
Study 19302015 — intervention group
Group type: COMPARATOR
Intervention: Placebo cluster-probe with no output
Number of subjects: 8
Study 19302015 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-diode 810-nm 200-mW laser
Number of subjects: 8
Study 16421747 — intervention group
Group type: EXPERIMENTAL
Intervention: Early neuromuscular customized training (ETG) starting 2 weeks after surgery
Number of subjects: 56
Study 16421747 — intervention group
Group type: COMPARATOR
Intervention: Traditional training (CG) starting 6 weeks after surgery
Number of subjects: 56
Study 15191483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bra
Number of subjects: 58
Study 15191483 — intervention group
Group type: COMPARATOR
Intervention: Binder
Number of subjects: 58
Study 11330759 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line drugs treatment for six months
Number of subjects: 24
Study 8979282 — intervention group
Group type: EXPERIMENTAL
Intervention: AA + DHA formula (0.12 wt% DHA and 0.43 wt% AA from egg yolk phospholipid)
Number of subjects: 197
Study 8979282 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA formula (0.2 wt% DHA from fish oil)
Number of subjects: 197
Study 8979282 — intervention group
Group type: COMPARATOR
Intervention: Control formula (no added LCP fatty acids)
Number of subjects: 197
Study 8979282 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed group
Number of subjects: 197
Study 8163425 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone breast implants
Number of subjects: 0
Study 2438878 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (Roaccutane) for 8 weeks
Number of subjects: 12
Study 2438878 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate (Tigason) for 8 weeks
Number of subjects: 12
Study 2438878 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12
Study 29395632 — intervention group
Group type: EXPERIMENTAL
Intervention: Education on symptoms management and training modifications
Number of subjects: 58
Study 29395632 — intervention group
Group type: EXPERIMENTAL
Intervention: Education+Exercise program
Number of subjects: 58
Study 29395632 — intervention group
Group type: EXPERIMENTAL
Intervention: Education+Gait retraining
Number of subjects: 58
Study 29395632 — intervention group
Group type: EXPERIMENTAL
Intervention: Education component (common to all interventions)
Number of subjects: 58
Study 29395632 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 58
Study 27113123 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment services
Number of subjects: 449
Study 25659620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical exercise training and nutritional intervention (EN group, n = 30)
Number of subjects: 89
Study 25659620 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training only (E group, n = 28)
Number of subjects: 89
Study 25659620 — intervention group
Group type: COMPARATOR
Intervention: Control group (C, n = 31)
Number of subjects: 89
Study 23089188 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged burst pacing without analgesia and sedation (Group B)
Number of subjects: 104
Study 23089188 — intervention group
Group type: COMPARATOR
Intervention: T‐wave shock under analgesia and sedation (Group T)
Number of subjects: 104
Study 23089188 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuron‐specific enolase levels after 6, 24, and 48 h (both groups)
Number of subjects: 104
Study 21905250 — intervention group
Group type: COMPARATOR
Intervention: Placebo arm of a 2-year study
Number of subjects: 622
Study 19140498 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone therapy (2.5 mg daily for 1 year)
Number of subjects: 26
Study 17043253 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 100
Study 17043253 — intervention group
Group type: COMPARATOR
Intervention: Conventional hemostasis (CH)
Number of subjects: 100
Study 12883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive behavioral therapy
Number of subjects: 60
Study 12883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychotherapy
Number of subjects: 60
Study 12883103 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 60
Study 10575080 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconstrained compensatory stepping evoked by platform translation (no specific instructions)
Number of subjects: 5
Study 10575080 — intervention group
Group type: EXPERIMENTAL
Intervention: Constrained compensatory stepping cued by platform translation (prior instruction to step rapidly)
Number of subjects: 5
Study 10575080 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid voluntary stepping to a light cue
Number of subjects: 5
Study 8571194 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid protamine administration (1.5 mg/kg over 3 minutes)
Number of subjects: 15
Study 8571194 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow protamine administration (1.5 mg/kg over 15 minutes)
Number of subjects: 15
Study 1929241 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (0.25 mg/kg)
Number of subjects: 23
Study 1929241 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B colloidal dispersion (1.5 mg/kg)
Number of subjects: 23
Study 1929241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 6886033 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment
Number of subjects: 29
Study 31797473 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin (30 mg/day)
Number of subjects: 84
Study 31797473 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron aqueous extract (SAE) (30 mg/day)
Number of subjects: 84
Study 31797473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 31586644 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + aPDT (photodynamic therapy)
Number of subjects: 114
Study 31586644 — intervention group
Group type: COMPARATOR
Intervention: SRP (control group)
Number of subjects: 114
Study 29478239 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06669571 (1 mg to 3 mg over 7 days)
Number of subjects: 20
Study 29478239 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo)
Number of subjects: 20
Study 29478239 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06669571
Number of subjects: 20
Study 29478239 — intervention group
Group type: COMPARATOR
Intervention: PF-06669571 and Placebo
Number of subjects: 20
Study 27693003 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 puffs of e-cigarette vapor (ECV) for 10 minutes
Number of subjects: 16
Study 25274899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tanezumab 5 mg
Number of subjects: 1668
Study 25274899 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tanezumab 10 mg
Number of subjects: 1668
Study 25274899 — intervention group
Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 1668
Study 25274899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1668
Study 23113833 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of atorvastatin daily plus SAR236553 once every 2 weeks
Number of subjects: 92
Study 23113833 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of atorvastatin daily plus SAR236553 once every 2 weeks
Number of subjects: 92
Study 23113833 — intervention group
Group type: COMPARATOR
Intervention: 80 mg of atorvastatin daily plus placebo once every 2 weeks
Number of subjects: 92
Study 23113833 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR236553 (combined with atorvastatin)
Number of subjects: 92
Study 23113833 — intervention group
Group type: COMPARATOR
Intervention: 80 mg of atorvastatin plus placebo
Number of subjects: 92
Study 20352415 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 18
Study 20352415 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg modafinil
Number of subjects: 18
Study 20352415 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18845960 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral-naive mothers and infants
Number of subjects: 980
Study 18845960 — intervention group
Group type: COMPARATOR
Intervention: Single-dose nevirapine or perinatal zidovudine treatment
Number of subjects: 980
Study 15911239 — intervention group
Group type: COMPARATOR
Intervention: Glutamine levels at Day 0 in patients with ALL
Number of subjects: 45
Study 15911239 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine levels in Group M (CNS disease present)
Number of subjects: 45
Study 15911239 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine and asparagine concentrations at Day 14 in Group L
Number of subjects: 45
Study 15911239 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamic acid amounts at Day 14 in Group L
Number of subjects: 45
Study 15911239 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine levels at Day 42 in Group M
Number of subjects: 45
Study 12621013 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK infusion at 0.40 IDU/kg over 20 min
Number of subjects: 44
Study 12621013 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK infusion at 0.40 IDU/kg
Number of subjects: 44
Study 12621013 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of two DCG studies in phase 3
Number of subjects: 44
Study 10836213 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB at 28 degrees C (Group H)
Number of subjects: 24
Study 10836213 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB at 32 degrees C (Group M)
Number of subjects: 24
Study 10836213 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermia (>36 degrees C) (Group N)
Number of subjects: 24
Study 10836213 — intervention group
Group type: COMPARATOR
Intervention: Overall comparison of sjvO2 and a-jvO2
Number of subjects: 24
Study 10836213 — intervention group
Group type: COMPARATOR
Intervention: Sjv(lactate)
Number of subjects: 24
Study 8656155 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared attributes
Number of subjects: 5
Study 8656155 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared causal relations
Number of subjects: 5
Study 8656155 — intervention group
Group type: EXPERIMENTAL
Intervention: Binding causal relations
Number of subjects: 5
Study 8656155 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncausal relation and familiar animal categories
Number of subjects: 5
Study 1462984 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc diethylene-triamine pentaacetic acid (Tc-DTPA) GFR estimation
Number of subjects: 24
Study 1462984 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation using the equation of Cockcroft and Gault
Number of subjects: 24